Coherus Oncology (CHRS) Competitors $1.64 -0.02 (-1.20%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.30%) As of 10/3/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. DAWN, TYRA, GYRE, PRME, NRIX, DNA, TERN, ANAB, PVLA, and MGTXShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Day One Biopharmaceuticals (DAWN), Tyra Biosciences (TYRA), Gyre Therapeutics (GYRE), Prime Medicine (PRME), Nurix Therapeutics (NRIX), Ginkgo Bioworks (DNA), Terns Pharmaceuticals (TERN), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors Day One Biopharmaceuticals Tyra Biosciences Gyre Therapeutics Prime Medicine Nurix Therapeutics Ginkgo Bioworks Terns Pharmaceuticals AnaptysBio Palvella Therapeutics MeiraGTx Day One Biopharmaceuticals (NASDAQ:DAWN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Does the media prefer DAWN or CHRS? In the previous week, Coherus Oncology had 2 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 4 mentions for Coherus Oncology and 2 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.92 beat Coherus Oncology's score of 0.53 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, DAWN or CHRS? Day One Biopharmaceuticals has a beta of -1.26, indicating that its share price is 226% less volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Which has higher valuation and earnings, DAWN or CHRS? Coherus Oncology has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M6.21-$95.50M-$0.95-8.37Coherus Oncology$266.96M0.71$28.51M$1.551.06 Is DAWN or CHRS more profitable? Coherus Oncology has a net margin of 125.90% compared to Day One Biopharmaceuticals' net margin of -50.63%. Coherus Oncology's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-50.63% -19.01% -16.99% Coherus Oncology 125.90%N/A -34.85% Do analysts prefer DAWN or CHRS? Day One Biopharmaceuticals presently has a consensus price target of $25.29, indicating a potential upside of 218.06%. Coherus Oncology has a consensus price target of $4.51, indicating a potential upside of 175.15%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Day One Biopharmaceuticals is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Coherus Oncology 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do insiders and institutionals believe in DAWN or CHRS? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCoherus Oncology beats Day One Biopharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.94M$3.31B$6.06B$10.58BDividend YieldN/A2.27%5.68%4.69%P/E Ratio1.0621.7377.3326.67Price / Sales0.71461.33606.06133.17Price / Cash5.6946.6137.7361.25Price / Book-1.449.9312.556.55Net Income$28.51M-$52.59M$3.30B$277.26M7 Day Performance9.33%5.22%28,056.13%2.37%1 Month Performance25.19%13.01%28,993.65%9.30%1 Year Performance57.69%25.19%35,460.84%30.78% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology4.2134 of 5 stars$1.64-1.2%$4.51+175.2%+57.7%$192.94M$266.96M1.06330News CoverageDAWNDay One Biopharmaceuticals3.0567 of 5 stars$6.99+3.2%$25.29+261.7%-42.4%$693.46M$131.16M-7.3660TYRATyra Biosciences2.0889 of 5 stars$13.30+2.5%$31.86+139.5%-36.7%$691.26MN/A-7.4720Analyst UpgradeGYREGyre Therapeutics1.1553 of 5 stars$7.50+4.7%$18.00+140.0%-39.5%$689.60M$105.76M750.7540PRMEPrime Medicine1.038 of 5 stars$5.32+3.9%N/AN/A$689.02M$2.98M-3.41N/ANews CoverageNRIXNurix Therapeutics2.1185 of 5 stars$9.28+3.9%$29.07+213.3%-56.7%$682.69M$54.55M-3.56300Upcoming EarningsDNAGinkgo Bioworks1.62 of 5 stars$13.20+14.8%$9.00-31.8%+98.8%$680.80M$227.04M-2.25640TERNTerns Pharmaceuticals3.7669 of 5 stars$7.79+2.0%$15.49+98.8%+0.4%$668.58MN/A-7.4940Positive NewsANABAnaptysBio2.7233 of 5 stars$23.27-1.3%$46.13+98.2%-11.7%$660.17M$91.28M-5.19100Trending NewsAnalyst ForecastAnalyst RevisionPVLAPalvella Therapeutics2.4936 of 5 stars$62.25+4.5%$67.09+7.8%N/A$659.04M$42.81M-5.14N/AAnalyst ForecastMGTXMeiraGTx3.8584 of 5 stars$8.25+0.9%$24.00+190.9%+106.1%$658.06M$33.28M-4.04300Positive NewsGap Up Related Companies and Tools Related Companies Day One Biopharmaceuticals Alternatives Tyra Biosciences Alternatives Gyre Therapeutics Alternatives Prime Medicine Alternatives Nurix Therapeutics Alternatives Ginkgo Bioworks Alternatives Terns Pharmaceuticals Alternatives AnaptysBio Alternatives Palvella Therapeutics Alternatives MeiraGTx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
